American Society of Hematology

Latest stories

4d
Business Wire
Phase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO (ixazomib) Published in The New England Journal of MedicineNINLARO (ixazomib) capsules. Data from TOURMALINE-MM1 were previously presente
Phase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO (ixazomib) Published in The New England Journal of Medicine
Business Wire / Posted 4 days ago
NINLARO (ixazomib) capsules. Data from TOURMALINE-MM1 were previously presented at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. NINLARO is currently under review by the European Medicines Agency... Read more
11d
Business Wire
Juno’s Investigational CAR T Cell Product Candidates JCAR018 and JTCR016 Demonstrate Encouraging Clinical Responses in Patients with B-Cell and Mesothelioma Cancersin this Phase I dose-escalation trial. (JCAR018; Clinical Trials Identifier: NC
Juno’s Investigational CAR T Cell Product Candidates JCAR018 and JTCR016 Demonstrate Encouraging Clinical Responses in Patients with B-Cell and Mesothelioma Cancers
Business Wire / Posted 11 days ago
in this Phase I dose-escalation trial. (JCAR018; Clinical Trials Identifier: NCT02315612). As previously reported at the American Society of Hematology meeting in December 2015, six patients were treated at the lowest dose, with one patient... Read more
13d
Business Wire
bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual MeetingThursday, May 5, 2016 Time: 4:00 – 4:15 p.m. Location: Washington 5-6 Note:
bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting
Business Wire / Posted 13 days ago
Thursday, May 5, 2016 Time: 4:00 – 4:15 p.m. Location: Washington 5-6 Note: Data previously presented at the 2015 American Society of Hematology Annual Meeting Title: Towards the Clinical Application of BCMA CAR T cells: The Importance of... Read more
25d
San Antonio Express-News
bluebird bio, Inc. vs. Alnylam Pharmaceuticalsexperimental candidate might a best-in-class product based on a small prelimina
bluebird bio, Inc. vs. Alnylam Pharmaceuticals
San Antonio Express-News / Posted 25 days ago
experimental candidate might a best-in-class product based on a small preliminary study presented at last year's Annual American Society of Hematology meeting. That said, the therapy still has a long way to go before its potential as a viable... Read more

People in this news